Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Posthoc data analysis from the phase 3 randomize d, open-lab el study comparing trab ecte din and PLD versus PLD alone in patients with recurrent ovarian cancer

被引：1

作者：

Monk, Bradley J. ^{[1
]}

Herzog, Thomas J. ^{[2
]}

Wang, George ^{[3
]}

Triantos, Spyros ^{[3
]}

Maul, Scott ^{[4
]}

Knoblauch, Roland ^{[3
]}

McGowan, Tracy ^{[5
]}

Shalaby, Waleed S. W. ^{[5
]}

Coleman, Robert L. ^{[6
]}

机构：

[1] Creighton Univ, Univ Arizona, US Oncol Network, Arizona Oncol, Phoenix, AZ 85012 USA

[2] Univ Cincinnati, Canc Ctr, Cincinnati, OH USA

[3] Janssen Res & Dev, Spring House, PA USA

[4] Janssen Res & Dev, Los Angeles, CA USA

[5] Janssen Sci Affairs LLC, Horsham, PA USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

DATA IN BRIEF | 2020年 / 30卷

关键词：

Overall survival; Pegylated liposomal doxorubicin; Trabectedin; Recurrent ovarian cancer; Response rate;

D O I：

10.1016/j.dib.2020.105465

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The data presented herein are supplementary to our published primary article "A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer"[1]. The exploratory analysis evaluated the impact of prior pegylated liposomal doxorubicin (PLD) therapy in patients who participated in a randomized, open-label study comparing combination therapy of trabectedin and PLD vs PLD alone in third-line recurrent ovarian cancer (ROC). These exploratory analyses showed that prior treatment with PLD in ROC does not impact the response and survival rates nor does it increase toxicities or negatively influence survival and response rates in both treatment groups. (C) 2020 The Author(s). Published by Elsevier Inc.

引用

页数：7

共 50 条

[41] INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
Colombo, N.
Gadducci, A.
Sehouli, J.
Rulli, E.
Maenpaa, J.
Sessa, C.
Montes, A.
Ottevanger, N. B.
Berger, R.
Vergote, I.
D'Incalci, M.
Galaz, C. Churruca
Chekerov, R.
Nyvang, G. B.
Riniker, S.
Herbertson, R.
Fossati, R.
Barretina-Ginesta, M. P.
Deryal, M.
Mirza, M. R.
Biagioli, E.
Iglesias, M.
Funari, G.
Romeo, M.
Tasca, G.
Pardo, B.
Tognon, G.
Rubio-Perez, M. J.
DeCensi, A.
De Giorgi, U.
Zola, P.
Panici, P. Benedetti
Aglietta, M.
Arcangeli, V.
Zamagni, C.
Bologna, A.
Westermann, A.
Heinzelmann-Schwarz, V.
Tsibulak, I.
Wimberger, P.
Poveda, A.
BRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1503 - 1513
[42] INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
N. Colombo
A. Gadducci
J. Sehouli
E. Rulli
J. Mäenpää
C. Sessa
A. Montes
N. B. Ottevanger
R. Berger
I. Vergote
M. D’Incalci
C. Churruca Galaz
R. Chekerov
G. B. Nyvang
S. Riniker
R. Herbertson
R. Fossati
M. P. Barretina-Ginesta
M. Deryal
M. R. Mirza
E. Biagioli
M. Iglesias
G. Funari
M. Romeo
G. Tasca
B. Pardo
G. Tognon
M. J. Rubio-Pérez
A. DeCensi
U. De Giorgi
P. Zola
P. Benedetti Panici
M. Aglietta
V. Arcangeli
C. Zamagni
A. Bologna
A. Westermann
V. Heinzelmann-Schwarz
I. Tsibulak
P. Wimberger
A. Poveda
British Journal of Cancer, 2023, 128 (8) : 1503 - 1513
[43] <bold>Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): Results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone. </bold>
Kong, B.
Biakhov, M.
Kelley, J. L.
Nunez, J.
Lebedinsky, C.
Parekh, T. V.
Vermorken, J. B.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[44] Trabectedin plus pegylated liposomal doxorubicin (PLD) prior to subsequent platinum chemotherapy in patients with platinum-resistant (PR) recurrent ovarian cancer (ROC): Results from OVA-301 follow-up.
Colombo, Nicoletta
Casado, Antonio
Fernandez, Consuelo
Vergote, Ignace
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results
O'Cearbhaill, R. E.
Homicsko, K.
Wolfer, A.
DiSilvestro, P. A.
O'Malley, D. M.
Sabbatini, P.
Orcurto, A.
Barras, D.
Shohara, L.
Ricciardi, T.
Macri, M.
Ryan, A.
Venhaus, R. R.
Monk, B. J.
Coukos, G.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 41 - 41
[46] Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) - an Exploratory Analysis
Vergote, I.
Bidzinski, M.
Kelley, J.
Vasanthan, S.
Runnebaum, I.
Vermorken, J.
Arranz, J. A.
Almorin, E.
Park, Y.
Lisyanskaya, A.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S536 - S536
[47] CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.
Gaillard, Stephanie
Ghamande, Sharad A.
Pardo, Beatriz
Lorusso, Domenica
Vergote, Ignace
Papai, Zsuzsanna
O'Malley, D.
Kristeleit, Rebecca Sophie
Redondo, Andres
Timcheva, Constanta
Fernandez, Cristian
Nieto, Antonio
Soto-Matos, Arturo
Moss, Keren Rachel
Baumann, Klaus H.
Ray-Coquard, Isabelle
Oaknin, Ana
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[48] A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An JNRG Oncology/Gynecologic Oncology Group study
Landrum, Lisa M.
Brady, William E.
Armstrong, Deborah K.
Moore, Kathleen N.
DiSilvestro, Paul A.
O'Malley, David M.
Tenney, Meaghan E.
Rose, Peter G.
Fracasso, Paula M.
GYNECOLOGIC ONCOLOGY, 2016, 140 (02) : 204 - 209
[49] A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: A Gynecologic Oncology Group study
Landrum, L. M.
Brady, W. E.
Armstrong, D. K.
Moore, K. N.
DiSilvestro, P. A.
O'Malley, D. M.
Tenney, M. E.
Rose, P. G.
Fracasso, P. M.
GYNECOLOGIC ONCOLOGY, 2015, 137 : 23 - 23
[50] A comparison of overall survival (OS) between 40 and 50mg/m2 pegylated liposomal doxorubicin (PLD) in recurrent epithelial ovarian cancer (OC) patients (pts): Propensity score (ProS) matched analysis of real world data
Yoshizawa, K.
Nakayama, M.
Kobayashi, H.
Nishimura, Y.
Kameyama, S.
Takahara, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S544 - S545

← 1 2 3 4 5 →